article thumbnail

NGS is changing GxP compliance. Will you adapt?

Bio Pharma Dive

Discover NGS for GxP compliance with full audit trails, operational control and robust data security.

article thumbnail

Biopharma & medical devices cos view advanced infrastructure to propel manufacturing & new drug development

AuroBlog - Aurous Healthcare Clinical Trials blog

It ensures scalability, quality control, and regulatory compliance. By investing in advanced labs, manufacturing facilities, regulatory compliance systems, cybersecurity, and global supply chains, companies can ensure they meet […]

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

MR dosage forms revolutionize patient compliance: Girish Nihalani

AuroBlog - Aurous Healthcare Clinical Trials blog

In the ever-evolving pharmaceutical landscape, modified release (MR) dosage forms have emerged as a groundbreaking innovation, providing solutions that significantly improve patient compliance by simplifying complex drug regimens.

article thumbnail

Mastering compliance and copyright in healthcare and MedComms

Pharmaceutical Technology

Understanding reuse rights and copyright compliance is critical, particularly in todays ever-evolving technological landscape.

article thumbnail

AI in Pharma Marketing: Innovation or Compliance Nightmare?

Pharma Marketing Network

But as pharma marketers race to adopt these tools, a central question looms: Is AI fueling smarter engagement, or setting the stage for a compliance disaster? Efficiency Gains : Generative AI tools can streamline content productionsaving time on medical writing, compliance reviews, and campaign development. Key pillars include: 1.

article thumbnail

NABL issues clarification on CAB combined ILAC MRA mark for effective compliance

AuroBlog - Aurous Healthcare Clinical Trials blog

The National Accreditation Board for Testing and Calibration Laboratories (NABL) has issued clarification on NABL accredited Conformity Assessment Body (CAB) combined International Laboratory Accreditation Co-operation (ILAC) Mutual Recognition Arrangement (MRA) mark for effective compliance.

article thumbnail

Compliance Challenges in Generic Drug Development: Lessons Learned

Drug Patent Watch

In our latest blog post, we delve into the compliance hurdles that generic drug developers face, and the valuable lessons learned from these experiences. This not only helps to ensure compliance, but also fosters a culture of trust and cooperation within the industry. Share your experiences with us in the comments below!